Skip to main content
Missouri Medicine logoLink to Missouri Medicine
letter
. 2020 Nov-Dec;117(6):530–531.

Cannabis and Pregnancy Don’t Mix

Albert Stuart Reece 1, Gary Kenneth Hulse 1
PMCID: PMC7721409  PMID: 33311778

In the September/October 2020 Missouri Medicine, Polocaro and Vettraino raise the important issue of the transgenerational effects of prenatal cannabinoid exposure (PCE) on subsequent generations.1 The implications of multigenerational toxicity of cannabinoids is very far-reaching with major policy implications.

The picture presented by Polcaro and Vettraino relating to the mental health implications of PCE is correct if too conservative. As they observe the subject is deeply confounded with multiple other factors impacting post-natal neurological development. For these reasons the significant concordance between reports from five longitudinal studies of childhood development relating to impaired indices of concentration, startle, excitability, poor visuospatial processing and executive functioning including ADHD-like and autism-like features are of particular concern.2-6 Under a legalization paradigm the state effectively condones unlimited all day every day exposure to extremely high concentrations of THC, other cannabinoids and cannabis tars. What is especially concerning about this is that many of the neurotoxic and neurodevelopmental toxicities of cannabis exhibit threshold dose effects above which severe damage becomes commonplace.7 In the context of an increasingly solid consensus relating to the harmful impacts of adult and adolescent cannabis exposure8 the implications of PCE-neurotoxicity have not been carefully considered. It has been shown that nationwide autism rates are undergoing an exponential rise and indeed New Jersey has been shown to have 4.5% of 8-year-old boys who carry an autism spectrum disorder diagnosis.9,10 Our space-time and causal inference studies demonstrate that indeed cannabinoid exposure to THC and cannabigerol amongst other fractions of cannabis, is a principal driver of this nationwide epidemic (manuscript submitted).9,10

A very concerning consensus is now emerging relating to cannabis-induced teratogenesis, embryotoxicity and fetotoxicity. A 2007 Hawaiian study found that 21 birth defects including many cardiovascular defects, Downs syndrome, orofacial clefts, gastroschisis and arm and hand defects were elevated in offspring of women exposed only to cannabis gestationally with odds ratios up to 40-fold and upper confidence intervals to 123-fold.11 A report on Canada found that total congenital defects were three times more common in the northern territories where cannabis is smoked about three times as much.12,13 In October 2018 Colorado Health reported an excess of 20,152 total birth defects beyond their baseline expected 67,620 defects 2000–2013 across the period of cannabis legalization when the use of other drugs was falling, representing an elevation of 29.8% above background rates.14 In a high cannabis use area of Australia 13 defects were found to be elevated compared to Queensland, which for methodological reasons is a conservative estimate.15 Concerningly elevated rates of Downs syndrome in Colorado, Hawaii, Australia and Canada clearly indicate that heritable cannabis genotoxicity can occur at the hundred megabase chromosomal scale.11,12,14,15 A close association of atrial septal defect (secundum type) with rising patterns of cannabis use across space and time in the US was recently reported, suggesting that the list of known teratological associations of prenatal cannabis exposure is as yet incomplete.16 This epidemiological literature is closely concordant with studies in experimental animals.1719 Again an abrupt rise in genotoxicity with increasing cannabinoid exposure has been demonstrated for many cannabinoids and is of particular concern.2023

Links between cannabis and several paediatric cancers including acute lymphoid leukaemia (ALL), acute myeloid leukaemia, rhabdomyosarcoma and neuroblastoma suggest further implications of cannabinoid genotoxicity.2428 Since these tumours together encompass the common tumours of childhood, it is at least possible that cannabis is responsible for the 43% elevation in total childhood cancer across US 1975–2017.29 Indeed Downs syndrome is well known to be associated with a 2,000-fold elevated risk of childhood ALL from 2/100,000 to around 5/100.30,31

This diverse assemblage of highly congruent evidence of severe cannabis-related neurotoxicity and genotoxicity from varied locations can only be described as extremely concerning indeed. In view of its well described epigenetic and chromoanagenetic effects3234 and its clearly transgenerational-multigenerational impacts one can only conclude that if the evidence base is not admitted to the cannabis debate and access to fetotoxic and embryotoxic cannabinoids is not immediately restricted the community will inevitably pay a heinous price in terms of avoidable paediatric neurotoxicity, congenital birth defects, heritable cancerogenesis and multigenerational epigenotoxicity.

References

  • 1.Polocaro J, Vettraino IM. Cannabis in Pregnancy and Lactation - A Review. Missouri Medicine. 2020;117:400–405. [PMC free article] [PubMed] [Google Scholar]
  • 2.Brents L. Correlates and consequences of Prenatal Cannabis Exposure (PCE): Identifying and Characterizing Vulnerable Maternal Populations and Determining Outcomes in Exposed Offspring. In: Preedy VR, editor. Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis and Treatment. Vol. 1. London: Academic Press; 2017. pp. 160–170. [Google Scholar]
  • 3.Smith AM, Mioduszewski O, Hatchard T, Byron-Alhassan A, Fall C, Fried PA. Prenatal marijuana exposure impacts executive functioning into young adulthood: An fMRI study. Neurotoxicol Teratol. 2016;58:53–59. doi: 10.1016/j.ntt.2016.05.010. [DOI] [PubMed] [Google Scholar]
  • 4.Smith AM, Longo CA, Fried PA, Hogan MJ, Cameron I. Effects of marijuana on visuospatial working memory: an fMRI study in young adults. Psychopharmacology (Berl) 2010;210(3):429–438. doi: 10.1007/s00213-010-1841-8. [DOI] [PubMed] [Google Scholar]
  • 5.Paul SE, Hatoum AS, Fine JD, et al. Associations Between Prenatal Cannabis Exposure and Childhood Outcomes: Results From the ABCD Study. JAMA Psychiatry. 2020:e202902. doi: 10.1001/jamapsychiatry.2020.2902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Fine JD, Moreau AL, Karcher NR, et al. Association of Prenatal Cannabis Exposure With Psychosis Proneness Among Children in the Adolescent Brain Cognitive Development (ABCD) Study. JAMA Psychiatry. 2019;76(7):762–764. doi: 10.1001/jamapsychiatry.2019.0076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Spencer S, Neuhofer D, Chioma VC, et al. A Model of Delta(9)-Tetrahydrocannabinol Self-administration and Reinstatement That Alters Synaptic Plasticity in Nucleus Accumbens. Biol Psychiatry. 2018;84(8):601–610. doi: 10.1016/j.biopsych.2018.04.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Reece AS, Hulse GK. Co-occurrence across time and space of drug- and cannabinoid- exposure and adverse mental health outcomes in the National Survey of Drug Use and Health: combined geotemporospatial and causal inference analysis. BMC Public Health. 2020;20(1):1655. doi: 10.1186/s12889-020-09748-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Reece AS, Hulse GK. Effect of Cannabis Legalization on US Autism Incidence and Medium Term Projections. Clinical Pediatrics: Open Access. 2019;4(2):1–17. [Google Scholar]
  • 10.Reece AS, Hulse GK. Epidemiological Associations of Various Substances and Multiple Cannabinoids with Autism in USA. Clinical Pediatrics: Open Access. 2019;4(2):1–20. [Google Scholar]
  • 11.Forrester MB, Merz RD. Risk of selected birth defects with prenatal illicit drug use, Hawaii, 1986–2002. Journal of toxicology and environmental health. 2007;70(1):7–18. doi: 10.1080/15287390600748799. [DOI] [PubMed] [Google Scholar]
  • 12.Reece AS, Hulse GK. Canadian Cannabis Consumption and Patterns of Congenital Anomalies: An Ecological Geospatial Analysis. J Addict Med. 2020;14(5):e195–e210. doi: 10.1097/ADM.0000000000000638. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Reece AS, Hulse GK. Cannabis Consumption Patterns Parallel the East-West Gradient in Canadian Neural Tube Defect Incidence: An Ecological Study. Global Pediatric Health. 2019;6 doi: 10.1177/2333794X19894798. 1222794X19894798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Reece AS, Hulse GK. Cannabis Teratology Explains Current Patterns of Coloradan Congenital Defects: The Contribution of Increased Cannabinoid Exposure to Rising Teratological Trends. Clin Pediatr (Phila) 2019;58(10):1085–1123. doi: 10.1177/0009922819861281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Reece AS, Hulse GK. Broad Spectrum Epidemiological Contribution of Cannabis and Other Substances to the Teratological Profile of Northern New South Wales: Geospatial and Causal Inference Analysis BMC Pharmacology and Toxicology. 2020;21(1):75–102. doi: 10.1186/s40360-020-00450-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Reece AS, Hulse GK. Contemporary Epidemiology of Rising Atrial Septal Defect Trends Across USA 1991–2016. A Combined Ecological Geospatiotemporal and Causal Inferential Study. BMC Pediatrics. 2020 doi: 10.1186/s12887-020-02431-z. In Press. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Graham JDP. Cannabis and Health. In: Graham JDP, editor. Cannabis and Health. 1 ed. Vol. 1. London, New York, San Francisco: Academic Press; 1976. pp. 271–320. [Google Scholar]
  • 18.Geber WF, Schramm LC. Effect of marihuana extract on fetal hamsters and rabbits. Toxicology and applied pharmacology. 1969;14(2):276–282. doi: 10.1016/0041-008x(69)90108-2. [DOI] [PubMed] [Google Scholar]
  • 19.Geber WF, Schramm LC. Teratogenicity of marihuana extract as influenced by plant origin and seasonal variation. Arch Int Pharmacodyn Ther. 1969;177(1):224–230. [PubMed] [Google Scholar]
  • 20.Shoyama Y, Sugawa C, Tanaka H, Morimoto S. Cannabinoids act as necrosis-inducing factors in Cannabis sativa. Plant Signal Behav. 2008;3(12):1111–1112. doi: 10.4161/psb.3.12.7011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Fisar Z, Singh N, Hroudova J. Cannabinoid-induced changes in respiration of brain mitochondria. Toxicology letters. 2014;231(1):62–71. doi: 10.1016/j.toxlet.2014.09.002. [DOI] [PubMed] [Google Scholar]
  • 22.Singh N, Hroudova J, Fisar Z. Cannabinoid-Induced Changes in the Activity of Electron Transport Chain Complexes of Brain Mitochondria. J Mol Neurosci. 2015;56(4):926–931. doi: 10.1007/s12031-015-0545-2. [DOI] [PubMed] [Google Scholar]
  • 23.Russo C, Ferk F, Misik M, et al. Low doses of widely consumed cannabinoids (cannabidiol and cannabidivarin) cause DNA damage and chromosomal aberrations in human-derived cells. Archives of toxicology. 2019;93(1):179–188. doi: 10.1007/s00204-018-2322-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Kuijten RR, Bunin GR, Nass CC, Meadows AT. Gestational and familial risk factors for childhood astrocytoma: results of a case-control study. Cancer Res. 1990;50(9):2608–2612. [PubMed] [Google Scholar]
  • 25.Robison LL, Buckley JD, Daigle AE, et al. Maternal drug use and risk of childhood nonlymphoblastic leukemia among offspring. An epidemiologic investigation implicating marijuana (a report from the Childrens Cancer Study Group) Cancer. 1989;63(10):1904–1911. [PubMed] [Google Scholar]
  • 26.Trivers KF, Mertens AC, Ross JA, et al. Parental marijuana use and risk of childhood acute myeloid leukaemia: a report from the Children’s Cancer Group (United States and Canada) Paediatric and perinatal epidemiology. 2006;20(2):110–118. doi: 10.1111/j.1365-3016.2006.00700.x. [DOI] [PubMed] [Google Scholar]
  • 27.Grufferman S, Schwartz AG, Ruymann FB, Maurer HM. Parents’ use of cocaine and marijuana and increased risk of rhabdomyosarcoma in their children. Cancer Causes Control. 1993;4(3):217–224. doi: 10.1007/BF00051316. [DOI] [PubMed] [Google Scholar]
  • 28.Wen WQ, Shu XO, Steinbuch M, et al. Paternal military service and risk for childhood leukemia in offspring. Am J Epidemiol. 2000;151(3):231–240. doi: 10.1093/oxfordjournals.aje.a010198. [DOI] [PubMed] [Google Scholar]
  • 29.National Cancer Institute. SEaERSP. SEER Explorer. National Cancer Institute, Surveillance Epidemiology and End Results (SEER) Program. [Accessed August 6th, 2020]. 2020. https://seer.cancer.gov/explorer/application.html. Published 2020.
  • 30.Birger Y, Shiloh R, Izraeli S. Mechanisms of Leukemia Evolution: Lessons from a Congenital Syndrome. Cancer Cell. 2019;36(2):115–117. doi: 10.1016/j.ccell.2019.07.004. [DOI] [PubMed] [Google Scholar]
  • 31.Labuhn M, Perkins K, Matzk S, et al. Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. Cancer Cell. 2019;36(2):123–138.e110. doi: 10.1016/j.ccell.2019.06.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Reece AS, Hulse GK. Chromothripsis and epigenomics complete causality criteria for cannabis- and addiction-connected carcinogenicity, congenital toxicity and heritable genotoxicity. Mutat Res. 2016;789:15–25. doi: 10.1016/j.mrfmmm.2016.05.002. [DOI] [PubMed] [Google Scholar]
  • 33.Reece AS, Hulse GK. Impacts of Cannabinoid Epigenetics on Human Development: Reflections on Murphy et. al. ‘Cannabinoid Exposure and Altered DNA Methylation in Rat and Human Sperm’ Epigenetics 2018; 13: 1208–1221. Epigenetics. 2019:1–16. doi: 10.1080/15592294.2019.1633868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Reece AS, Wang W, Hulse GK. Pathways from epigenomics and glycobiology towards novel biomarkers of addiction and its radical cure. Medical hypotheses. 2018;116:10–21. doi: 10.1016/j.mehy.2018.04.011. [DOI] [PubMed] [Google Scholar]

Articles from Missouri Medicine are provided here courtesy of Missouri State Medical Association

RESOURCES